Zacks Research Issues Negative Forecast for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report issued on Monday, January 27th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($0.97) per share for the quarter, down from their previous forecast of ($0.96). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($3.11) EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.67 EPS and FY2026 earnings at $1.86 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The firm’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.15 earnings per share.

A number of other research analysts have also recently weighed in on ALNY. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, January 21st. Scotiabank increased their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $273.99 on Thursday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market cap of $35.34 billion, a price-to-earnings ratio of -104.58 and a beta of 0.34. The company’s 50 day moving average is $249.42 and its two-hundred day moving average is $260.65.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock valued at $20,622,925 in the last quarter. 1.50% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Algert Global LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $476,000. Creative Planning boosted its holdings in shares of Alnylam Pharmaceuticals by 63.2% during the 2nd quarter. Creative Planning now owns 8,034 shares of the biopharmaceutical company’s stock worth $1,952,000 after purchasing an additional 3,110 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Alnylam Pharmaceuticals by 72.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 596 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 250 shares during the last quarter. Regal Investment Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 4.1% during the second quarter. Regal Investment Advisors LLC now owns 3,348 shares of the biopharmaceutical company’s stock worth $814,000 after buying an additional 132 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $578,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.